Tyrosine Protein Kinase JAK3 (Janus Kinase 3 or Leukocyte Janus Kinase or JAK3 or EC 2.7.10.2) – Pipeline Review, H2 2017

Global Markets Direct’s, ‘Tyrosine Protein Kinase JAK3 (Janus Kinase 3 or Leukocyte Janus Kinase or JAK3 or EC 2.7.10.2) – Pipeline Review, H2 2017’, provides in depth analysis on Tyrosine Protein Kinase JAK3 (Janus Kinase 3 or Leukocyte Janus Kinase or JAK3 or EC 2.7.10.2) targeted pipeline therapeutics. The report provides comprehensive information complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Tyrosine Protein Kinase JAK3 (Janus Kinase 3 or Leukocyte Janus Kinase or JAK3 or EC 2.7.10.2) targeted therapeutics development and features dormant and discontinued projects. The report analyses the pipeline products from therapy areas Immunology, Dermatology, Gastrointestinal, Oncology, Musculoskeletal Disorders, Ophthalmology and Respiratory under development targeting Tyrosine Protein Kinase JAK3 (Janus Kinase 3 or Leukocyte Janus Kinase or JAK3 or EC 2.7.10.2).

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

*Updated report will be delivered in 48 hours of order confirmation.

Scope

The report provides a snapshot of the global therapeutic landscape for Tyrosine Protein Kinase JAK3 (Janus Kinase 3 or Leukocyte Janus Kinase or JAK3 or EC 2.7.10.2)

The report reviews Tyrosine Protein Kinase JAK3 (Janus Kinase 3 or Leukocyte Janus Kinase or JAK3 or EC 2.7.10.2) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Tyrosine Protein Kinase JAK3 (Janus Kinase 3 or Leukocyte Janus Kinase or JAK3 or EC 2.7.10.2) targeted therapeutics and enlists all their major and minor projects

The report assesses Tyrosine Protein Kinase JAK3 (Janus Kinase 3 or Leukocyte Janus Kinase or JAK3 or EC 2.7.10.2) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Tyrosine Protein Kinase JAK3 (Janus Kinase 3 or Leukocyte Janus Kinase or JAK3 or EC 2.7.10.2) targeted therapeutics

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Tyrosine Protein Kinase JAK3 (Janus Kinase 3 or Leukocyte Janus Kinase or JAK3 or EC 2.7.10.2)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Tyrosine Protein Kinase JAK3 (Janus Kinase 3 or Leukocyte Janus Kinase or JAK3 or EC 2.7.10.2) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Companies mentioned

Aclaris Therapeutics Inc

Arrien Pharmaceuticals LLC

Astellas Pharma Inc

Bristol-Myers Squibb Co

Chipscreen Biosciences Ltd

Clevexel Pharma SAS

Japan Tobacco Inc

LSK BioPartners Inc

Merck & Co Inc

MYOS RENS Technology Inc

Pfizer Inc

Portola Pharmaceuticals Inc

Sienna Biopharmaceuticals Inc

Simcere Pharmaceutical Group

Theravance Biopharma Inc

Vectura Group Plc

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 6

List of Figures 6

Introduction 7

Global Markets Direct Report Coverage 7

Tyrosine Protein Kinase JAK3 (Janus Kinase 3 or Leukocyte Janus Kinase or JAK3 or EC

2.7.10.2) - Overview 8

Tyrosine Protein Kinase JAK3 (Janus Kinase 3 or Leukocyte Janus Kinase or JAK3 or EC

2.7.10.2) - Therapeutics Development 9

Products under Development by Stage of Development 9

Products under Development by Therapy Area 10

Products under Development by Indication 11

Products under Development by Companies 14

Tyrosine Protein Kinase JAK3 (Janus Kinase 3 or Leukocyte Janus Kinase or JAK3 or EC

2.7.10.2) - Therapeutics Assessment 19

Assessment by Mechanism of Action 19

Assessment by Route of Administration 20

Assessment by Molecule Type 22

Tyrosine Protein Kinase JAK3 (Janus Kinase 3 or Leukocyte Janus Kinase or JAK3 or EC

2.7.10.2) - Companies Involved in Therapeutics Development 23

Aclaris Therapeutics Inc 23

Arrien Pharmaceuticals LLC 23

Astellas Pharma Inc 23

Bristol-Myers Squibb Co 24

Chipscreen Biosciences Ltd 24

Clevexel Pharma SAS 25

Japan Tobacco Inc 25

LSK BioPartners Inc 26

Merck & Co Inc 26

MYOS RENS Technology Inc 27

Pfizer Inc 27

Portola Pharmaceuticals Inc 28

Sienna Biopharmaceuticals Inc 29

Simcere Pharmaceutical Group 29

Theravance Biopharma Inc 30

Vectura Group Plc 30

Tyrosine Protein Kinase JAK3 (Janus Kinase 3 or Leukocyte Janus Kinase or JAK3 or EC

2.7.10.2) - Drug Profiles 32

ARN-4079 - Drug Profile 32

Product Description 32

Mechanism Of Action 32

R&D Progress 32

ATI-50001 - Drug Profile 33

Product Description 33

Mechanism Of Action 33

R&D Progress 33

ATI-50002 - Drug Profile 35

Product Description 35

Mechanism Of Action 35

R&D Progress 35

ATI-50003 - Drug Profile 36

Product Description 36

Mechanism Of Action 36

R&D Progress 36

cerdulatinib - Drug Profile 37

Product Description 37

Mechanism Of Action 37

R&D Progress 37

CS-510 - Drug Profile 42

Product Description 42

Mechanism Of Action 42

R&D Progress 42

CS-944X - Drug Profile 43

Product Description 43

Mechanism Of Action 43

R&D Progress 43

CVXL-0074 - Drug Profile 44

Product Description 44

Mechanism Of Action 44

R&D Progress 44

JTE-052 - Drug Profile 45

Product Description 45

Mechanism Of Action 45

R&D Progress 45

KBP-7536 - Drug Profile 47

Product Description 47

Mechanism Of Action 47

R&D Progress 47

LSK-9985 - Drug Profile 48

Product Description 48

Mechanism Of Action 48

R&D Progress 48

OST-122 - Drug Profile 49

Product Description 49

Mechanism Of Action 49

R&D Progress 49

peficitinib hydrobromide - Drug Profile 50

Product Description 50

Mechanism Of Action 50

R&D Progress 50

PF-06651600 - Drug Profile 53

Product Description 53

Mechanism Of Action 53

R&D Progress 53

Small Molecule to Inhibit JAK3 for Heart Transplantation - Drug Profile 54

Product Description 54

Mechanism Of Action 54

R&D Progress 54

Small Molecules to Inhibit JAK1 and JAK3 for Autoimmune Diseases and Inflammation - Drug Profile 55

Product Description 55

Mechanism Of Action 55

R&D Progress 55

Small Molecules to Inhibit JAK2 and JAK3 for Oncology and Auto Immune Disease - Drug Profile 56

Product Description 56

Mechanism Of Action 56

R&D Progress 56

Small Molecules to Inhibit JAK3 for Rheumatoid Arthritis - Drug Profile 57

Product Description 57

Mechanism Of Action 57

R&D Progress 57

Small Molecules to Inhibit JAK3 for Rheumatoid Arthritis - Drug Profile 58

Product Description 58

Mechanism Of Action 58

R&D Progress 58

Small Molecules to Inhibit JAK3 for Rheumatoid Arthritis, Sarcopenia and Cachexia - Drug Profile 59

Product Description 59

Mechanism Of Action 59

R&D Progress 59

SNA-125 - Drug Profile 60

Product Description 60

Mechanism Of Action 60

R&D Progress 60

TD-1473 - Drug Profile 61

Product Description 61

Mechanism Of Action 61

R&D Progress 61

TD-3504 - Drug Profile 63

Product Description 63

Mechanism Of Action 63

R&D Progress 63

tofacitinib citrate - Drug Profile 64

Product Description 64

Mechanism Of Action 64

R&D Progress 64

VR-588 - Drug Profile 82

Product Description 82

Mechanism Of Action 82

R&D Progress 82

Tyrosine Protein Kinase JAK3 (Janus Kinase 3 or Leukocyte Janus Kinase or JAK3 or EC

2.7.10.2) - Dormant Products 83

Tyrosine Protein Kinase JAK3 (Janus Kinase 3 or Leukocyte Janus Kinase or JAK3 or EC

2.7.10.2) - Discontinued Products 86

Tyrosine Protein Kinase JAK3 (Janus Kinase 3 or Leukocyte Janus Kinase or JAK3 or EC

2.7.10.2) - Product Development Milestones 87

Featured News & Press Releases 87

Oct 16, 2017: New Ulcerative Colitis Data for XELJANZ (tofacitinib)at Upcoming Gastroenterology Congresses 87

Sep 08, 2017: NICE issues positive recommendation for XELJANZ (tofacitinib citrate) as a new treatment option for adults with severe rheumatoid arthritis 88

Aug 28, 2017: Studies reveal how shingles vaccine should be used in arthritis patients 89

Aug 08, 2017: Theravance Biopharma Reports Encouraging Data from First Cohort of Patients in Phase 1b Clinical Trial of TD-1473 in Ulcerative Colitis 89

Aug 03, 2017: Fda Advisory Committee Votes In Favor Of XELJANZ (Tofacitinib Citrate) For The Treatment Of Active Psoriatic Arthritis 91

Aug 02, 2017: Aclaris Therapeutics Submits Investigational New Drug Application for ATI-50002 to Treat Alopecia Areata 91

Jul 13, 2017: Pfizer Announces FDA Accepts Supplemental New Drug Application For Xeljanz (Tofacitinib Citrate) For The Treatment Of Adult Patients With Moderately To Severely Active Ulcerative Colitis 92

Jun 23, 2017: European Hematology Association: Two is better than one: The Dual SYK/JAK Inhibitor Cerdulatinib Demonstrates Rapid Tumor Responses in a Phase 2 Study for Relapsed/Refractory NHL 92

Jun 16, 2017: Pfizer Announces Results From XELJANZ (Tofacitinib Citrate) Oral Strategy Study Published In The Lancet And Presented At The EULAR Annual Congress 93

Jun 15, 2017: Portola Pharmaceuticals Presents Interim Phase 2a Safety and Efficacy Data for Cerdulatinib at the International Congress of Malignant Lymphoma 94

May 18, 2017: Portola Pharmaceuticals Announces Phase 2a Safety and Efficacy Cerdulatinib Data to be Presented at the European Hematology Association 95

May 09, 2017: Portola Pharmaceuticals Announces Cerdulatinib Data to be Presented at the International Conference on Malignant Lymphoma 96

May 05, 2017: Aclaris Therapeutics Completes Phase 1 Clinical Trial of ATI-50001 for the Treatment of Alopecia Universalis and Alopecia Totalis 96

May 03, 2017: Pfizer Announces U.S. FDA Filing Acceptance Of Supplemental New Drug Application For Xeljanz (Tofacitinib Citrate) For The Treatment Of Adult Patients With Active Psoriatic Arthritis 97

May 03, 2017: Phase 3 Octave Studies Of Oral Tofacitinib In Ulcerative Colitis Results Published In The New England Journal Of Medicine 97

Appendix 100

Methodology 100

Coverage 100

Secondary Research 100

Primary Research 100

Expert Panel Validation 100

Contact Us 100

Disclaimer 101

List of Tables

List of Tables

Number of Products under Development by Stage of Development, H2 2017 9

Number of Products under Development by Therapy Areas, H2 2017 10

Number of Products under Development by Indications, H2 2017 11

Number of Products under Development by Indications, H2 2017 (Contd..1), H2 2017 13

Number of Products under Development by Companies, H2 2017 14

Products under Development by Companies, H2 2017 15

Products under Development by Companies, H2 2017 (Contd..1), H2 2017 16

Products under Development by Companies, H2 2017 (Contd..2), H2 2017 17

Products under Development by Companies, H2 2017 (Contd..3), H2 2017 18

Number of Products by Stage and Mechanism of Actions, H2 2017 19

Number of Products by Stage and Route of Administration, H2 2017 21

Number of Products by Stage and Molecule Type, H2 2017 22

Pipeline by Aclaris Therapeutics Inc, H2 2017 23

Pipeline by Arrien Pharmaceuticals LLC, H2 2017 23

Pipeline by Astellas Pharma Inc, H2 2017 24

Pipeline by Bristol-Myers Squibb Co, H2 2017 24

Pipeline by Chipscreen Biosciences Ltd, H2 2017 25

Pipeline by Clevexel Pharma SAS, H2 2017 25

Pipeline by Japan Tobacco Inc, H2 2017 26

Pipeline by LSK BioPartners Inc, H2 2017 26

Pipeline by Merck & Co Inc, H2 2017 27

Pipeline by MYOS RENS Technology Inc, H2 2017 27

Pipeline by Pfizer Inc, H2 2017 28

Pipeline by Portola Pharmaceuticals Inc, H2 2017 29

Pipeline by Sienna Biopharmaceuticals Inc, H2 2017 29

Pipeline by Simcere Pharmaceutical Group, H2 2017 30

Pipeline by Theravance Biopharma Inc, H2 2017 30

Pipeline by Vectura Group Plc, H2 2017 31

Dormant Products, H2 2017 83

Dormant Products, H2 2017 (Contd..1), H2 2017 84

Dormant Products, H2 2017 (Contd..2), H2 2017 85

Discontinued Products, H2 2017 86

List of Figures

List of Figures

Number of Products under Development by Stage of Development, H2 2017 9

Number of Products under Development by Therapy Areas, H2 2017 10

Number of Products under Development by Indications, H2 2017 11

Number of Products by Stage and Mechanism of Actions, H2 2017 19

Number of Products by Routes of Administration, H2 2017 20

Number of Products by Stage and Routes of Administration, H2 2017 20

Number of Products by Stage and Molecule Type, H2 2017 22

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports